$ALDR Announces Presentations at 69th Annual American Academy of Neurology Meeting

0
384

Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention

Alder BioPharmaceuticals, Inc. (ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data for eptinezumab (formerly ALD403), which is in clinical development for the prevention of migraine, will be presented at the upcoming 69th Annual American Academy of Neurology meeting on April 22-28, 2017 in Boston.
  • Platform presentation: Randomized, Double-Blind, Placebo-Controlled Trial of ALD403, an Anti-CGRP Peptide Antibody in the Prevention of Chronic Migraine

    Session: S52, Headache: Clinical Trials and Disease Burden
    Date: Friday, April 28, 2017
    Presenter: Dr. David Dodick
    Time: 1:24 p.m.
    Location:  Boston Convention and Exhibition Center

  • Poster presentation: Rational Design of a Monoclonal Antibody (mAb) Inhibiting Calcitonin Gene-Related Peptide (CGRP), ALD403, Intended for the Prevention of Migraine

    Poster: #155
    Date: Monday, April 24
    Poster Q & A Session: 5:30 p.m. – 7:00 p.m. EDT
    Location:  Boston Convention and Exhibition Center, Poster Session II

  • Poster presentation: 75% Responder Rates Provide Improvement in HIT-6 Scores from Week 4 Through 12 Following a Single Infusion of ALD403, or Placebo

    Poster: #165
    Date: Monday, April 24
    Poster Q & A Session: 5:30 p.m. – 7:00 p.m. EDT
    Location: Boston Convention and Exhibition Center, Poster Session II

LEAVE A REPLY

Please enter your comment!
Please enter your name here